

09 June 2021  
 ASX Code: MXC  
 LSE Code: MXC

## Appointment of Company Secretary

**MGC Pharmaceuticals Ltd (ASX, LSE: MXC, 'MGC Pharma' or 'the Company')**, would like to confirm the appointment of Mr David Lim CPA AGIA as joint Company Secretary of the Company with immediate effect.

Mr Lim is a finance and corporate governance professional with over 15 years of experience working for ASX Listed companies. He has previously performed the role of Group CFO and Company Secretary at a number of ASX listed businesses including Equigold NL, Aurora Oil and Gas and Elixir Petroleum.

Mr Lim is a Certified Practising Accountant and holds a Graduate Diploma of Applied Corporate Governance from, and is an Associate member of, the Governance Institute of Australia.

**Roby Zomer, Co-founder and Managing Director of MGC Pharma, commented:** "David joins MGC Pharma at an exciting time for the business, as we make significant progress on clinical trials across our product line, most notably with the Stage III trials of CimetrA™. We all look forward to working with David and to utilising his previous experience in other listed businesses in Australia."

--Ends--

**Authorised for release by the Board, for further information please contact:**

**MGC Pharmaceuticals Ltd**

Roby Zomer  
 CEO & Managing Director  
 +61 8 6382 3390  
[info@mgcpharma.com.au](mailto:info@mgcpharma.com.au)

**UK Broker – Turner Pope**

Andy Thacker  
 +44 203 657 0050  
[info@turnerpope.com](mailto:info@turnerpope.com)

**UK PR Advisors – Tavistock**

Tim Pearson  
 +44 207 920 3150  
[Tim.Pearson@tavistock.co.uk](mailto:Tim.Pearson@tavistock.co.uk)

**Australian IR Advisors – Media & Capital Partners**

Rod Hinchcliffe  
 +61 412 277 377  
[Rod.Hinchcliffe@mcpartners.com.au](mailto:Rod.Hinchcliffe@mcpartners.com.au)

### About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based bio-pharma company developing and supplying affordable standardised phytocannabinoid derived medicines to patients globally. The Company's founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality phytocannabinoid derived medicines for the growing demand in the medical markets in Europe, North America and Australasia. MGC Pharma has a robust product offering targeting two widespread medical conditions – epilepsy and dementia – and has further products in the development pipeline.

Employing its 'Nature to Medicine' strategy, MGC Pharma has partnered with renowned institutions and academia to optimise cultivation and the development of targeted phytocannabinoid derived medicines products prior to production in the Company's EU-GMP Certified manufacturing facility.

MGC Pharma has a number of research collaborations with world renowned academic institutions, and including recent research highlighting the positive impact of using specific phytocannabinoid formulations developed by MGC Pharma in the treatment of glioblastoma, the most aggressive and so far therapeutically resistant primary brain tumour.

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.

Follow us through our social media channels    

A  
 S  
 X  
 R  
 E  
 L  
 E  
 A  
 S  
 E